Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study seeks to gain new information on why young women with anorexia nervosa are
predisposed to early bone loss and osteoporosis. Through a randomized treatment trial in
which participants will receive either combined therapy with the adrenal hormone,
dehydroepiandrosterone (DHEA) and estrogen replacement therapy or placebo, we will determine
the effects of an 18-month treatment course on bone mass, circulating markers of bone
turnover, and serum levels of a factor, insulin-like growth factor I (IGF-I). We are also
studying if these therapies change bone structure to increase skeletal strength compared to
placebo, as assessed through cross-sectional geometric analysis of our bone density data by
dual-energy x-ray absorptiometry (DXA).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) United States Department of Defense